View more job listings or post a job
PPD, Inc. Senior Scientist - Quality Control - HPLC - Dissolution - Method Validation
Aligos Therapeutics Director DMPK
Genentech Senior Scientific Researcher, DMPK
Genentech Scientist/Sr. Scientist Small Molecule - In Vitro DMPK
ChemoCentryx Director, Toxicology
PPD, Inc. Scientist-HPLC, GC          
Escient Pharmaceuticals Scientist - DMPK  
ChemoCentryx Inc. Senior Research Associate to Scientist I, DMPK
Precision for Medicine Senior Scientific Director, Bioanalytical Sciences
Post a job

Seminar luncheon

Convertible CAR-T cells with a steering wheel, accelerator, and brake for cancer therapy

Speakers: David W. Martin, MD, Chairman and Chief Scientific Officer, Xyphos Bioscience
Organizers: Shichang Miao, PhD
Date: 2018-12-14
Time: 11:00-14:00 Pacific Time
Registration fee (USD): Major Sponsor: $2000; Vegetarian $0: $0; Chicken $0: $0; Fish $0: $0
Location: SF Bay Area: Foster City Crowne Plaza
Major Sponsor:
Vendor show vendors registered to date: (4)BioTechne (R&D Systems); DyChrom; Novogene Corporation; PHC former Panasonic Healthcare
Registration deadline:2018-12-11  (it will close sooner if the seating cap is reached)

About the Topic

The recent progress in the field of immuno-oncology has dramatically changed the clinical approach to treating cancer. Tremendous excitement centers on Adoptive Cell Therapy (ACT), an approach that delivers living cells derived from the human immune system and engineered to target and kill cancer cells. Results from numerous clinical studies of pioneer CAR-T therapy products showed tremendous success and provided evidence of complete and durable cancer remissions. However, at the same time, many challenges to effect safe and effective CAR-T therapy became evident.

Building on the success of the pioneer CAR-T therapies, Xyphos is developing best-in-class CAR-T therapy products based on our ACCEL technology which includes our universal 
CAR and a family of bispecific, antibody-like adaptor molecules, called MicAbodies™ and MicAdaptors. Our vision is to provide precision, control, safety and ultimately durable efficacy to this revolutionary class of cancer therapy. Further details are at

About the Speakers

DAVID W. MARTIN, MD, Chairman and Chief Scientific Officer

Dr. Martin is a Co-founder of Xyphos. He has previously held executive and scientific leadership roles in biotechnology and pharmaceutical companies including SVP of R&D at Genentech (1982-1990); Executive VP of R&D at DuPont Merck (1991-1993); President of Chiron Therapeutics (1994-1995); and Founder and CEO of Eos Biotechnology (1997-2003); and Co-founder and CEO of AvidBiotics (2004-2017). Additionally, he has served as Director and Lead Director of Cubist Pharmaceuticals and Varian Medical Systems, each for more than a decade. Dr. Martin trained at Duke Medical School, was Professor of Medicine and Biochemistry at University of California, San Francisco, and Investigator of the Howard Hughes Medical Institute. He is currently a member of the Oversight Committee for the California Institute for Regenerative Medicine.

2019-06-11, Advances in Immuno-Oncology (A Joint Symposium by PBSS and BioScience Forum)
2019-07-26, Learnings From Biocatalytic Pharmaceutical Manufacture Applied to Generating Efficacious Enzyme Therapeutics
2019-09-13, Biotransformation and Disposition of Larger Molecules: Peptides, Nucleotides, Proteins, mAbs, and ADCs
2019-10-03, Small-Molecule Bioanalytical Method Validation & Regulated Bioanalysis: Fundamentals, the New FDA Guidance and Regulatory Trends
2019-10-18, Physiologically Based Pharmacokinetic (PBPK) Modeling: Fundamentals, Regulatory Guidance & Applications
2019-11-12, Antibody Drug Discovery and Development: Hit Generation, Engineering, Cell-line Development, IND enabling studies, and Biosimilars
2020-02-11, Drug-Device Combination
┬ęPharmaceutical & BioScience Society, International; Last Modified: 5/21/2019; Visited: 447; Admin Logon
Ads (in random order)
Submit a Text Ad
($200 for 2 months)

Analiza PhysChem & ADME Analytical Services -Solubility, LogD/P, pKa, PAMPA, Metabolic Stability, Cyp 450 & More. FAST, FLEXIBLE, ACCURATE, AND AFFORDABLE!
Pacific BioLabs CRO in Bay Area - PK, toxicology, biocompatibility, analytical chemistry, immunogenicity, biomarker analysis, stability studies, sterility, endotoxin
MicroConstants MicroConstants is a GLP-compliant Contract Research Organization focused on performing regulated bioanalysis, drug metabolism and PK analysis.
Immunomind Scientific Consulting - Protocol Development, Data Analysis, Lab Guidance, Tech Transfer - Meeting your project goals at a moment's notice.
Viva Biotech World Leading CRO in Structural Biol. & Protein Sci.; Med. Chemistry; ASMS Screening; SPR; Fab/ant X-cryst; In Vitro Pharmacology; mAb discovery; GPCR
Hypha Discovery mg-g scale synthesis/purification of CYP/non-CYP metabolites including glucuronides. Plus NEW PolyCYPs kits for in-house synthesis of CYP metabolites.
Submit a Text Ad